Mednax, Inc (NYSE:MD) had its price target hoisted by analysts at Robert W. Baird from $47.00 to $48.00 in a research report issued on Friday. The firm presently has a “neutral” rating on the stock. Robert W. Baird’s price objective points to a potential upside of 10.68% from the company’s current price.

A number of other analysts have also issued reports on the stock. Jefferies Group LLC restated a “hold” rating and set a $44.00 target price on shares of Mednax in a research report on Friday. KeyCorp set a $51.00 price target on shares of Mednax and gave the company a “buy” rating in a report on Wednesday. BMO Capital Markets started coverage on shares of Mednax in a report on Monday, October 16th. They issued a “market perform” rating and a $46.00 price target on the stock. Zacks Investment Research upgraded shares of Mednax from a “sell” rating to a “hold” rating in a report on Wednesday, October 11th. Finally, BidaskClub lowered shares of Mednax from a “sell” rating to a “strong sell” rating in a report on Friday, August 4th. Two analysts have rated the stock with a sell rating, ten have given a hold rating and two have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $54.50.

Shares of Mednax (NYSE MD) opened at $43.37 on Friday. The company has a market cap of $4,061.82, a P/E ratio of 13.26, a PEG ratio of 1.41 and a beta of 0.32. Mednax has a 1 year low of $40.56 and a 1 year high of $72.13. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.37 and a quick ratio of 1.59.

Mednax (NYSE:MD) last announced its earnings results on Wednesday, November 1st. The company reported $0.87 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.87. Mednax had a net margin of 7.76% and a return on equity of 10.80%. The firm had revenue of $868.95 million for the quarter, compared to analyst estimates of $864.78 million. During the same quarter last year, the business earned $1.09 earnings per share. Mednax’s revenue was up 4.9% compared to the same quarter last year. sell-side analysts predict that Mednax will post 3.08 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This story was published by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.watchlistnews.com/robert-w-baird-increases-mednax-inc-md-price-target-to-48-00/1679922.html.

In related news, Director Cesar L. Alvarez sold 10,668 shares of Mednax stock in a transaction on Friday, November 3rd. The shares were sold at an average price of $42.59, for a total transaction of $454,350.12. Following the sale, the director now owns 44,215 shares of the company’s stock, valued at approximately $1,883,116.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider John C. Pepia sold 3,000 shares of the firm’s stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $42.85, for a total transaction of $128,550.00. Following the transaction, the insider now directly owns 35,569 shares of the company’s stock, valued at $1,524,131.65. The disclosure for this sale can be found here. Insiders own 2.40% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the business. BNP Paribas Arbitrage SA grew its holdings in Mednax by 415.0% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 272,172 shares of the company’s stock worth $11,736,000 after acquiring an additional 219,322 shares in the last quarter. FDx Advisors Inc. grew its holdings in Mednax by 55.9% during the 3rd quarter. FDx Advisors Inc. now owns 13,854 shares of the company’s stock worth $597,000 after acquiring an additional 4,970 shares in the last quarter. Swiss National Bank grew its holdings in Mednax by 0.4% during the 3rd quarter. Swiss National Bank now owns 343,000 shares of the company’s stock worth $14,790,000 after acquiring an additional 1,300 shares in the last quarter. IPG Investment Advisors LLC grew its holdings in Mednax by 52.6% during the 3rd quarter. IPG Investment Advisors LLC now owns 200,520 shares of the company’s stock worth $8,646,000 after acquiring an additional 69,130 shares in the last quarter. Finally, Principal Financial Group Inc. grew its holdings in Mednax by 0.7% during the 3rd quarter. Principal Financial Group Inc. now owns 398,057 shares of the company’s stock worth $17,164,000 after acquiring an additional 2,665 shares in the last quarter. 99.97% of the stock is owned by institutional investors.

Mednax Company Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Analyst Recommendations for Mednax (NYSE:MD)

Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.